MHRA Updates Valproate Guidelines for Men: A Closer Look
The Medicines and Healthcare products Regulatory Agency (MHRA) has revised its guidance on the use of sodium valproate in men. This new directive removes the requirement for dual specialist reviews for men who are already on the medication, simplifying the process in certain cases while maintaining safety precautions.
Key Changes in Valproate Guidelines for Men
In September 2024, the MHRA advised that men prescribed valproate and their female partners should use effective contraception while on the drug, and for three months following cessation. This precautionary guidance arose from research indicating a potential increased risk of neurodevelopmental disorders in children born to men treated with valproate in the three months before conception.
Following a review by the Commission on Human Medicines, the MHRA decided that men under 55 already taking valproate do not need a dual specialist review. However, the requirement remains for new male patients under 55 and for women under 55, unless reproductive risks are not applicable.
Assessing Risks Against Treatment Benefits
The initial restrictions faced criticism for stringent measures. A comprehensive evidence review suggested no substantial proof that paternal use of antiseizure medication poses a clear adverse effect on offspring outcomes. Experts concluded that the risks associated with less effective or alternative medications — including increased morbidity, mortality, and breakthrough seizures — are more significant than the “unlikely” risk to offspring.
Additionally, concerns emerged from studies involving women who experienced increased risks of sudden death in epilepsy due to restrictions on valproate. The drug is known for its teratogenic potential, presenting up to a 10% risk of birth defects and a 40% risk of developmental issues.
Continued Guidelines for Valproate Use
Under the revised guidelines, men already on valproate will be questioned at their next review about their plans to start a family in the next year. If they indicate such intentions, they will be referred to a specialist to discuss alternative treatment options. Existing regulations still permit the prescription of valproate to women of childbearing potential only if specialists deem other treatments ineffective or intolerable and if a robust pregnancy prevention program is in place.
Valproate as a Viable Option
Despite ongoing debates and restrictions, valproate remains a valid treatment option for many patients. Given its efficacy in controlling severe epileptic seizures, it continues to be essential amidst competing treatments that may lack similar potency.
Dr. Sheena Meredith, an experienced medical writer, editor, and consultant in healthcare communications, brings expertise in writing for a wide audience, combining her background in medicine with law and medical ethics.
Your Thoughts Matter
We invite you to share your thoughts on these changes in the comments section below. How do you think these new guidelines will impact patients and their healthcare providers? Share your insights and experiences with us.
Don’t forget to subscribe to our newsletter to stay updated on the latest healthcare news and developments. Follow us on social media for real-time updates and engaging content.
Like and share this article if you found it informative. Your support helps us bring more such valuable content to you.
